Gene Therapy Makes Strides for Infants With Spinal Muscular Atrophy
During the AAN 2021 Virtual Annual Meeting, investigators presented their findings on the safety and efficacy of onasemnogene abeparvovec (formerly AVXS-101) in presymptomatic SMA patients with 3 copies of the survival motor neuron 2 gene.